Literature DB >> 24791959

Impact of sepsis on CD4 T cell immunity.

Javier Cabrera-Perez1, Stephanie A Condotta2, Vladimir P Badovinac3, Thomas S Griffith4.   

Abstract

Sepsis remains the primary cause of death from infection in hospital patients, despite improvements in antibiotics and intensive-care practices. Patients who survive severe sepsis can display suppressed immune function, often manifested as an increased susceptibility to (and mortality from) nosocomial infections. Not only is there a significant reduction in the number of various immune cell populations during sepsis, but there is also decreased function in the remaining lymphocytes. Within the immune system, CD4 T cells are important players in the proper development of numerous cellular and humoral immune responses. Despite sufficient clinical evidence of CD4 T cell loss in septic patients of all ages, the impact of sepsis on CD4 T cell responses is not well understood. Recent findings suggest that CD4 T cell impairment is a multipronged problem that results from initial sepsis-induced cell loss. However, the subsequent lymphopenia-induced numerical recovery of the CD4 T cell compartment leads to intrinsic alterations in phenotype and effector function, reduced repertoire diversity, changes in the composition of naive antigen-specific CD4 T cell pools, and changes in the representation of different CD4 T cell subpopulations (e.g., increases in Treg frequency). This review focuses on sepsis-induced alterations within the CD4 T cell compartment that influence the ability of the immune system to control secondary heterologous infections. The understanding of how sepsis affects CD4 T cells through their numerical loss and recovery, as well as function, is important in the development of future treatments designed to restore CD4 T cells to their presepsis state.
© 2014 Society for Leukocyte Biology.

Entities:  

Keywords:  apoptosis; homeostatic proliferation; immune suppression; lymphopenia

Mesh:

Substances:

Year:  2014        PMID: 24791959      PMCID: PMC4197564          DOI: 10.1189/jlb.5MR0114-067R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  161 in total

1.  Inpatient care for septicemia or sepsis: a challenge for patients and hospitals.

Authors:  Margaret Jean Hall; Sonja N Williams; Carol J DeFrances; Aleksandr Golosinskiy
Journal:  NCHS Data Brief       Date:  2011-06

Review 2.  Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.

Authors:  K J Laing; L Dong; J Sidney; A Sette; D M Koelle
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

3.  Sepsis leads to a reduced antigen-specific primary antibody response.

Authors:  Arno Mohr; Johannes Polz; Elisabeth M Martin; Sybille Griessl; Anja Kammler; Christian Pötschke; Anja Lechner; Barbara M Bröker; Sven Mostböck; Daniela N Männel
Journal:  Eur J Immunol       Date:  2011-12-20       Impact factor: 5.532

4.  Analysis of peripheral blood lymphocyte subsets and prognosis in patients with septic shock.

Authors:  Xiaofeng Chen; Jilu Ye; Jun Ye
Journal:  Microbiol Immunol       Date:  2011-10       Impact factor: 1.955

5.  Immunosuppression in patients who die of sepsis and multiple organ failure.

Authors:  Jonathan S Boomer; Kathleen To; Kathy C Chang; Osamu Takasu; Dale F Osborne; Andrew H Walton; Traci L Bricker; Stephen D Jarman; Daniel Kreisel; Alexander S Krupnick; Anil Srivastava; Paul E Swanson; Jonathan M Green; Richard S Hotchkiss
Journal:  JAMA       Date:  2011-12-21       Impact factor: 56.272

6.  Immune unresponsiveness to secondary heterologous bacterial infection after sepsis induction is TRAIL dependent.

Authors:  Prajwal Gurung; Deepa Rai; Stephanie A Condotta; Jeffrey C Babcock; Vladimir P Badovinac; Thomas S Griffith
Journal:  J Immunol       Date:  2011-07-25       Impact factor: 5.422

7.  B cells enhance early innate immune responses during bacterial sepsis.

Authors:  Kindra M Kelly-Scumpia; Philip O Scumpia; Jason S Weinstein; Matthew J Delano; Alex G Cuenca; Dina C Nacionales; James L Wynn; Pui Y Lee; Yutaro Kumagai; Philip A Efron; Shizuo Akira; Clive Wasserfall; Mark A Atkinson; Lyle L Moldawer
Journal:  J Exp Med       Date:  2011-07-11       Impact factor: 14.307

8.  Protective contributions against invasive Streptococcus pneumoniae pneumonia of antibody and Th17-cell responses to nasopharyngeal colonisation.

Authors:  Jonathan M Cohen; Suneeta Khandavilli; Emilie Camberlein; Catherine Hyams; Helen E Baxendale; Jeremy S Brown
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

9.  Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients.

Authors:  Yan Zhang; Jinbao Li; Jingsheng Lou; Ying Zhou; Lulong Bo; Jiali Zhu; Keming Zhu; Xiaojian Wan; Zailong Cai; Xiaoming Deng
Journal:  Crit Care       Date:  2011-02-24       Impact factor: 9.097

10.  Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients.

Authors:  Caroline Guignant; Alain Lepape; Xin Huang; Hakim Kherouf; Laure Denis; Françoise Poitevin; Christophe Malcus; Aurélie Chéron; Bernard Allaouchiche; François Gueyffier; Alfred Ayala; Guillaume Monneret; Fabienne Venet
Journal:  Crit Care       Date:  2011-03-21       Impact factor: 9.097

View more
  50 in total

Review 1.  Enteric immunity, the gut microbiome, and sepsis: Rethinking the germ theory of disease.

Authors:  Javier Cabrera-Perez; Vladimir P Badovinac; Thomas S Griffith
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

2.  Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival.

Authors:  Derek B Danahy; Isaac J Jensen; Thomas S Griffith; Vladimir P Badovinac
Journal:  J Immunol       Date:  2019-04-10       Impact factor: 5.422

Review 3.  Clinical and Experimental Sepsis Impairs CD8 T-Cell-Mediated Immunity.

Authors:  Derek B Danahy; Robert K Strother; Vladimir P Badovinac; Thomas S Griffith
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

Review 4.  Advances in the understanding and treatment of sepsis-induced immunosuppression.

Authors:  Fabienne Venet; Guillaume Monneret
Journal:  Nat Rev Nephrol       Date:  2017-12-11       Impact factor: 28.314

5.  Immune Response Resetting in Ongoing Sepsis.

Authors:  Alexandre E Nowill; Márcia C Fornazin; Maria C Spago; Vicente Dorgan Neto; Vitória R P Pinheiro; Simônia S S Alexandre; Edgar O Moraes; Gustavo H M F Souza; Marcos N Eberlin; Lygia A Marques; Eduardo C Meurer; Gilberto C Franchi; Pedro O de Campos-Lima
Journal:  J Immunol       Date:  2019-07-29       Impact factor: 5.422

6.  Microbial Exposure Enhances Immunity to Pathogens Recognized by TLR2 but Increases Susceptibility to Cytokine Storm through TLR4 Sensitization.

Authors:  Matthew A Huggins; Frances V Sjaastad; Mark Pierson; Tamara A Kucaba; Whitney Swanson; Christopher Staley; Alexa R Weingarden; Isaac J Jensen; Derek B Danahy; Vladimir P Badovinac; Stephen C Jameson; Vaiva Vezys; David Masopust; Alexander Khoruts; Thomas S Griffith; Sara E Hamilton
Journal:  Cell Rep       Date:  2019-08-13       Impact factor: 9.423

7.  Perspectives on the Immune System in Sepsis.

Authors:  Felician Stancioiu; Bogdan Ivanescu; Radu Dumitrescu
Journal:  Maedica (Bucur)       Date:  2022-06

8.  Differential alterations of tissue T-cell subsets after sepsis.

Authors:  Archna Sharma; Weng-Lang Yang; Shingo Matsuo; Ping Wang
Journal:  Immunol Lett       Date:  2015-09-08       Impact factor: 3.685

Review 9.  HDL and persistent inflammation immunosuppression and catabolism syndrome.

Authors:  Grant Barker; Julia R Winer; Faheem W Guirgis; Srinivasa Reddy
Journal:  Curr Opin Lipidol       Date:  2021-10-01       Impact factor: 4.616

10.  Inducing Experimental Polymicrobial Sepsis by Cecal Ligation and Puncture.

Authors:  Frances V Sjaastad; Isaac J Jensen; Roger R Berton; Vladimir P Badovinac; Thomas S Griffith
Journal:  Curr Protoc Immunol       Date:  2020-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.